Pharmaceuticals

Latest California Healthline Stories

KFF Health News' 'What the Health?': Here Come the ACA Premium Hikes

Medicaid may have monopolized Washington’s attention lately, but big changes are coming to the Affordable Care Act as well. Meanwhile, Americans are learning more about what’s in Trump’s big budget law, and polls suggest many don’t like what they see. Julie Appleby of KFF Health News, Jessie Hellmann of CQ Roll Call, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more. Also this week, Rovner interviews historian Jonathan Oberlander to mark Medicare’s 60th anniversary.

KFF Health News' 'What the Health?': The Senate Saves PEPFAR Funding — For Now

The Senate narrowly approved the Trump administration’s request to claw back about $9 billion for foreign aid and public broadcasting but refused to cut funding for the international AIDS/HIV program PEPFAR. Meanwhile, a federal appeals court ruled that West Virginia can ban the abortion pill mifepristone, which could allow states to block other FDA-approved drugs. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine, Shefali Luthra of The 19th, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more.

Tal vez no es la edad, quizás tienes anemia

Los síntomas de la anemia —cansancio, dolor de cabeza, calambres en las piernas, frío, disminución de la capacidad para hacer ejercicio, confusión mental— a menudo se atribuyen al envejecimiento mismo.

KFF Health News' 'What the Health?': Supreme Court Upholds Bans on Gender-Affirming Care

The Supreme Court this week said Tennessee may continue to enforce its law banning most types of gender-affirming care for minors. The ruling is likely to greenlight similar laws in two dozen states. And the Senate is preparing to vote on a budget reconciliation bill that includes even deeper Medicaid cuts than the House version. Victoria Knight of Axios, Alice Miranda Ollstein of Politico, and Sandhya Raman of CQ Roll Call join KFF Health News’ Julie Rovner to discuss these stories and more.

Two Patients Faced Chemo. The One Who Survived Demanded a Test To See if It Was Safe.

Worried that President Donald Trump’s FDA might not act, a panel of cancer experts recommended that doctors consider testing before dosing patients with a commonly used but sometimes deadly cancer drug. It came too late for many patients.

Trump Exaggerates Speed and Certainty of Prescription Drug Price Reductions

According to the timeline in the May 12 executive order, prescription drug price reductions would not happen “almost immediately,” but rather could take months or years. And extending the savings to Americans outside federal health insurance programs such as Medicare would likely require congressional action.